Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
Bughani U, Saha A, Kuriakose A, Nair R, Sadashivarao RB, Venkataraman R, Patel S, Deshchougule AT, S SK, Montero E, Pai HV, Palanivelu DV, Melarkode R, Nair P. Bughani U, et al. Among authors: montero e. PLoS One. 2017 Jul 3;12(7):e0180088. doi: 10.1371/journal.pone.0180088. eCollection 2017. PLoS One. 2017. PMID: 28672038 Free PMC article.
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, Shah R, Gopal MG, Narayana Rao T, Srinivas CR, Bhat R, Shetty N, Manmohan G, Sai Krishna K, Padmaja D, Pratap DV, Garg V, Gupta S, Pandey N, Khopkar U, Montero E, Ramakrishnan MS, Nair P, Ganapathi PC. Krupashankar DS, et al. Among authors: montero e. J Am Acad Dermatol. 2014 Sep;71(3):484-92. doi: 10.1016/j.jaad.2014.01.897. Epub 2014 Apr 2. J Am Acad Dermatol. 2014. PMID: 24703722 Clinical Trial.
Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study.
Chopra A, Chandrashekara S, Iyer R, Rajasekhar L, Shetty N, Veeravalli SM, Ghosh A, Merchant M, Oak J, Londhey V, Barve A, Ramakrishnan MS, Montero E. Chopra A, et al. Among authors: montero e. Clin Rheumatol. 2016 Apr;35(4):1059-64. doi: 10.1007/s10067-015-2988-9. Epub 2015 Jun 7. Clin Rheumatol. 2016. PMID: 26050104 Clinical Trial.
Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.
Dogra S, D S K, Budamakuntla L, Srinivas CR, Khopkar U, Gupta S, Shetty N, Pratap DV, Gopal MG, Rao TN, Garg V, Sumathy TK, Saraswat A, Bhat R, Kura M, Pandey N, Shah R, Sai Krishna K, Padmaja D, Manmohan G, M S R, Barve A, Montero E. Dogra S, et al. Among authors: montero e. J Am Acad Dermatol. 2015 Aug;73(2):331-3.e1. doi: 10.1016/j.jaad.2015.03.040. J Am Acad Dermatol. 2015. PMID: 26183983 Clinical Trial. No abstract available.
Defining a cure for type 1 diabetes: a call to action.
Roep BO, Montero E, van Tienhoven R, Atkinson MA, Schatz DA, Mathieu C. Roep BO, et al. Among authors: montero e. Lancet Diabetes Endocrinol. 2021 Sep;9(9):553-555. doi: 10.1016/S2213-8587(21)00181-9. Epub 2021 Jul 30. Lancet Diabetes Endocrinol. 2021. PMID: 34339632 No abstract available.
370 results